Merck KGaA los recortes de personal de confirman.

German pharmaceutical and chemical company Merck KGaA said Tuesday it has agreed with labor representatives on a savings plan that involves 1,100 job cuts in Germany by 2015.
The job cuts will be across all the company divisions and will mainly result from voluntary resignations and early retirement programs, the company said in a statement.
There will be no forced redundancies at Merck's Darmstadt and Gernsheim sites through the end of 2017, workers council Chairman Heiner Wilhelm said.
The plan includes shutting down operations at the company's Lehrte site in northern Germany and in southern Germany's Hohenbrunn site.
Merck employs 10,900 people across Germany.
The measures are part of the Merck's efficiency program to secure long-term competitiveness, the company said. (Ver)

Ver también:

MERCK KGaA: Los re_cortes (de personal) no dejan ver el bosque (de las mergers).

"Big Pharma" en los paises (emergentes) de las maravillas.../ The $47 Billion Hole in Pharma's Near-Term Future

Big drug makers get hammered when their blockbuster drugs go off patent and face competition from generics. But most of them – including Pfizer, Merck, Eli Lilly, Bristol-Myers Squibb and Novo Nordisk – have hoped that rising sales in emerging markets would make up for that.

And that’s not going as planned, as the Wall Street Journal and YCharts have reported. Even when big pharma sells generics, local generics companies can undercut them by half. The result:

according to the Journal, Ernst & Young says pharma companies have been $47 billion too optimistic in terms of emerging market-sales over the next four years. (Ver)

Merck, which gets 18% of pharmaceutical and vaccine sales from emerging markets, still expects that to be 25% in 2013.

At Pfizer, emerging market sales rose 8% in the second quarter to $2.6 billion. But it has scaled back projections to low single digits.

At Bristol-Myers Squibb, last year emerging markets brought in $887 million, up 10% — the same percentage growth it had in the U.S.

Eli Lilly’s goal is to double 2010 emerging market sales to $4.6 billion in 2015. But it’s experiencing slower growth in China, says the Journal. In the second quarter, emerging market sales slipped 4%.